News | Ventricular Assist Devices (VAD) | October 06, 2015

Aortix Heart Failure Pump Chosen for TCT “Shark Tank” Competition

Panel of judges will vote on the best technological concepts of the year
 

Aortix device, TCT, Interventional Innovation Shark Tank Competition, catheter-based circulatory heart pump

Image courtesy of Procyrion

October 6, 2015 — The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in the Interventional Innovation “Shark Tank” Competition at the Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium. The event will be held Tuesday, Oct. 13, in San Francisco, California.

Developed by Procyrion Inc., Aortix is designed to be the first catheter-based circulatory heart pump specifically for New York Heart Association (NYHA) Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions. The small but powerful micro-pump is deployed downstream of the carotid arteries, which has the potential to eliminate major risks associated with thrombotic strokes, and the device is suitable for ambulatory use.

Duke University cardiologist and Procyrion Scientific Advisory Board member Manesh Patel, M.D., will have eight minutes to present the novel booster pump before a unique group of reviewers who will select the best technological concepts of the year. The top three finalists will be selected to answer additional questions from the judges and the winner and first-runner up will be announced Thursday, Oct. 15.

The Aortix device is not approved for use or sale.

For more information: www.procyrion.com

Related Content

The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

Feature | Heart Failure | August 21, 2020 | Dave Fornell, Editor
August 21, 2020 — The U.S.
Photo of Eyes Predicts Death and Readmission in Heart Failure Patients. Getty Images.

Photo of Eyes Predicts Death and Readmission in Heart Failure Patients. Getty Images.

News | Heart Failure | August 17, 2020
 
Examples of  allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs).

Examples of allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs), that were used to treat heart attack infarcts to reverse heart failure in the ALLSTAR trial.

News | Heart Failure | August 04, 2020
August 4, 2020 - More than three years after a clinical trial was prematurely ended for failing to show progress in h
News | Heart Failure | July 09, 2020
July 9, 2020 – The Minneapolis Heart Institute Foundation (MHIF) is conducting additional research on a novel hydroge
Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient to treat heart failure..

Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient.

News | Heart Failure | June 23, 2020
June 23, 2020 — The U.S.
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
News | Heart Failure | March 29, 2020
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure | March 28, 2020
March 28, 2020 — New data from a sub-analysis of the landmark Phase III...
News | Heart Failure | March 05, 2020
March 5, 2020 — Abbott recently received Breakthrough Device designation from the U.S.